Skip to main content
Premium Trial:

Request an Annual Quote

Cenix, Bayer Ink Deal to Screen Druggable Genes Using RNAi

NEW YORK, Dec. 15 (GenomeWeb News) - Cenix BioScience said today that it has signed a deal to use its genome-wide siRNA library to help Bayer screen all known human druggable genes in an effort to identify and validate new drug targets.

 

Cenix said that, using cell-based assays developed in partnership with Bayer researchers, it expects to screen more than 6,000 genes in less than nine months.

 

Under the terms of the deal, Cenix will receive upfront fees and research funding, and is eligible for milestone payments. Bayer will have an option to obtain all rights to new intellectual property generated by the effort.

 

Additional terms were not disclosed.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more